Almada Has Realized a Holding, Kamada and Matricelf Still Need Capacity to Become Revenue or a Trial
Almada completed a portfolio exit with expected proceeds of $12.6 million to the partnership, while Kamada and Matricelf reported milestones that improve capacity and clinical readiness but still need to translate into revenue or a trial. Compugen sits at the weaker end of the ladder: an AI/ML investor discussion without a contract, payment or new clinical milestone.
ALMEDA VENTURES completed the sale of BioProtect to Olympus on June 1, and that event provides a useful reference point for the recent biotech filings: not every milestone reaches the financial statements at the same speed. Almada already has total transaction consideration received by the trustee, expected proceeds to the partnership and an expected pre-tax, pre-success-fee gain. At KAMADA, FDA approval for the new RFFIT laboratory, a rabies antibody neutralization test, expands quality-control capacity around KEDRAB and KAMRAB, products that together generated more than $70 million of sales in 2025, but the financial effect still depends on lab utilization and less reliance on external testing. At MATRICELF, the start of GMP (good manufacturing practice) engineering runs brings the company closer to filing for a first human trial, while final safety results, regulatory approvals and additional funding remain necessary. COMPUGEN is at the other end of the ladder: participation in a Jones Trading AI/ML fireside chat strengthens the narrative frame, not cash, a contract or a clinical stage. The right read is therefore a quality ranking of biotech milestones, not a single story of sector progress.
A Completed Sale Carries More Weight Than Operational Progress
The ALMEDA VENTURES event is the most binding filing in this set. Olympus acquired 100% of BioProtect’s issued share capital on a fully diluted basis, and the full $270 million transaction consideration was received by the trustee. For the partnership itself, expected consideration from the sale of its full BioProtect stake is about $12.6 million, and the expected gain before tax and success fees is about $8 million.
The key point is not only the price. It is the cash path. Of ALMEDA VENTURES’s expected consideration, about $11.3 million was designated to reach the partnership’s bank account within days of completion, while the remaining amount will stay with the trustee for about three months and be transferred subject to the transaction terms. This is materially different from fair value in a private portfolio company: it starts moving value into the partnership’s cash account, even though the final calculation is still preliminary, unaudited and subject to adjustments, tax, expenses and success fees.
For a life-sciences investment partnership, that distinction is the quality filter. A fair-value gain can look good in a report, but it does not finance another investment and does not by itself enable a distribution to unit owners. A completed sale, with cash beginning to reach the partnership, changes liquidity before the final accounting is closed. BioProtect is therefore the only milestone in this set that already has a clear financial-statement path: cash in the partnership and a realized investment gain.
Regulatory Testing Capacity Still Needs Utilization
KAMADA received FDA approval on June 1 for a new RFFIT laboratory at its Beit Kama plant. The test measures rabies-neutralizing antibodies and is used throughout the manufacturing process for KEDRAB and KAMRAB, from plasma collection and sourcing through final product release. The lab had previously been approved by the Israeli Ministry of Health and Health Canada, and the US approval completes the key regulatory layer for the relevant products.
This approval matters because it relates to an existing commercial activity, not a distant research option. KEDRAB and KAMRAB represented a franchise of more than $70 million in 2025 sales, and in-house testing can contribute through quality control, lower dependence on external parties and support for production volumes. It is not a new contract or purchase order, so it does not have the immediate revenue path Almada has. The money shows up only if the lab becomes active utilization, better manufacturing efficiency or better product availability without expanding external costs.
The contrast with ALMEDA VENTURES is straightforward: Almada’s transaction has closed, while KAMADA’s operating capability has been approved. In a commercial biopharma company, that approval carries more weight than a routine research update because it is connected to products that already generated revenue. The next evidence point is lab use, not the approval itself. If future filings show that the lab supports sales, margin or product-release timing, the approval will deserve a higher economic weight.
Engineering Runs Move the Trial Path Forward and Keep Funding in Focus
MATRICELF reported on June 8 that it began clinical-scale engineering runs in clean rooms at Sheba’s Advanced Biotherapy Center. The company started three parallel runs based on human samples from healthy volunteers and is producing the cellular component of the implant, iPSCs (induced pluripotent stem cells) derived from blood samples. This is the first of three planned manufacturing stages: the cellular component, the extracellular hydrogel component derived from omentum tissue samples, and then the engineered neural tissue implant itself.
The MATRICELF update improves the quality of progress because it is about a manufacturing process, not a statement of intent. The company expects the second and third stages to begin during the next six months, and expects to complete production and analysis of the full engineering runs during the first quarter of 2027. If the runs meet the company’s quality, stability, safety and clinical-manufacturing criteria, they are intended to support a request for approval of a first human trial.
The remaining constraint is concrete. MATRICELF still needs final successful animal safety results, expected in the coming weeks, regulatory and ethics preparation, and additional budgetary resources to complete preparation and conduct the clinical trial. Israeli, US or other regulators may also require more information, documents, data, trials, tests, manufacturing processes or additional engineering runs. This is stronger than an investor call, but weaker than a completed sale or a regulatory approval tied to a product already generating sales.
An Investor Conversation Does Not Replace Clinical Data or a Deal
COMPUGEN announced on June 8 that it will participate on June 15 in a Jones Trading fireside chat with leaders in AI/ML-based drug development. The filing reminds investors of Unigen, the company’s computational discovery platform, and its four clinical-stage programs: COM701, COM902, rilvegostomig and GS-0321. It also repeats that MAIA-ovarian is a randomized blinded platform trial evaluating COM701, that rilvegostomig is being developed by AstraZeneca, and that GS-0321 is in Phase 1 under a license to Gilead.
This point matters mainly as a boundary. COMPUGEN is indeed active in a field where AI/ML is part of drug-target discovery, but participation in a discussion does not change the AstraZeneca or Gilead agreements, add a payment, or move a trial to a new stage. Compared with Almada, Kamada and Matricelf, it is not the same quality of evidence. It can put the company back into the AI/ML platform discussion, but value returns to the financial statements only through clinical data, a milestone payment, or deeper partnership economics.
| Company | What Was Published | What Is Already Binding | What Is Still Missing |
|---|---|---|---|
| ALMEDA VENTURES | Completion of the BioProtect sale to Olympus | Total consideration received by the trustee, about $11.3 million designated to reach the partnership within days of completion | Final net amount after adjustments, tax, expenses and success fees |
| KAMADA | FDA approval for the RFFIT lab in Beit Kama | Regulatory approval for internal testing capacity around KEDRAB and KAMRAB | Evidence that the lab improves utilization, timing, cost or product availability |
| MATRICELF | Start of GMP engineering runs at Sheba | Transition into clinical-scale trial manufacturing preparation | Safety results, completion of manufacturing stages, approvals and additional funding |
| COMPUGEN | Jones Trading AI/ML fireside chat | Reinforced framing around the drug-discovery platform | Clinical data, payment, contract or new development stage |
The Next Read Depends on Cash, Lab Use and Trial Entry
These filings rank biotech milestones by evidence quality, not headline strength. ALMEDA VENTURES leads because BioProtect has been sold and the payment path to the partnership is detailed. KAMADA follows because the approval strengthens existing operations and products that already generate sales, but the lab still needs to show economic use. MATRICELF moved forward on trial manufacturing, while safety results, regulation and funding still determine whether the path reaches a first human trial. COMPUGEN remains a narrative signal until it reports an event that moves the pipeline or commercial agreements.
The follow-up is simple: at Almada, how much net cash remains at the partnership after all adjustments; at Kamada, whether the lab shows up in utilization, margin or product availability; at Matricelf, whether the engineering runs and safety results support a first human trial request without overly heavy financing; and at Compugen, whether AI/ML discussions connect to a clinical update or partnership economics rather than staying an investor message.
Disclosure: Deep TASE analyses are general informational, research, and commentary content only. They do not constitute investment advice, investment marketing, a recommendation, or an offer to buy, sell, or hold any security, and are not tailored to any reader's personal circumstances.
The author, site owner, or related parties may hold, buy, sell, or otherwise trade securities or financial instruments related to the companies discussed, before or after publication, without prior notice and without any obligation to update the analysis. Publication of an analysis should not be read as a statement that any position does or does not exist.
The analysis may contain errors, omissions, or information that changes after publication. Readers should review official filings and primary sources before making decisions.